2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Clinical Procedures, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Biological Processes, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Immunology, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, B Cell Lymphoma, Indolent Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4006 Clinical feasibility and sensitivity of bone marrow minimal residual disease detection by next-generation sequencing in multiple myeloma in a real-world setting

Jessica M. Kent, N/A, Yuchen Jin2, Binod Dhakal, MD, MS3, Oren Pasvolsky, MD4, Mahmoud R. Gaballa, MD5, Hector Garcia Pleitez, MD6, Sarvari V. Yellapragada, MD7, Krina Patel Jr, MD, MSc8, Muzaffar Qazilbash, MD9, Anita D'Souza, MD10, Aniko Szabo, PhD11, Carolina D Schinke, MD12, Meera Mohan, MD, MS13
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 UT MD Anderson Cancer, Houston, Texas, United States
6 UT MD Anderson Cancer, Houston, Texas, United States
7 UT MD Anderson Cancer, Houston, Texas, United States
8 UT MD Anderson Cancer, Houston, Texas, United States
9 UT MD Anderson Cancer, Houston, Texas, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
13 UT MD Anderson Cancer, Houston, Texas, United States

Background: Bone marrow (BM) minimal residual disease (MRD) testing is an established endpoint in multiple myeloma (MM) clinical trials to measure disease response. The International Myeloma Working Group (IMWG) recognizes MRD negativity at a sensitivity of at least 10-5. Current MRD assays achieve sensitivities ranging from 10-4 to 10-6, with deeper levels of MRD negativity associated with better outcomes. MRD assessment using Next Generation Sequencing (NGS) is increasingly used in clinical practice. In this study, we assessed the feasibility of detecting a trackable baseline clonotype identification ID and the depth of sensitivity achievable by NGS-based MRD testing in real-world settings.

Methods: We identified MM patients who had a BM identification (ID) sample and MRD testing by NGS (ClonoSEQ) performed at 2 academic centers: Medical College of Wisconsin and University of Arkansas for Medical Sciences. Patients were included if they had BM MRD testing at any point during their disease course, regardless of treatment or disease status. Collected data included baseline ID sequences, number of tracked and detected ID sequences in subsequent tests, tumor cells detected per million counts, and number of cells assessed. The presence of any residual sequence was considered MRD positive (MRDpos), and its absence was MRD negative (MRDneg).

Results: A total of 647 unique patients were included. A baseline trackable baseline ID was identified in 90% of patients. Among these patients, majority (57%) had 2-3 trackable V(D)J sequences at baseline; 12% had 1, 18% had 4-5, and 2% had >5 sequences. A total of 1,411 MRD tests were performed among 595 patients. Overall, 686 (49%) of BM samples were MRDpos and 725 (51%) were MRDneg. The median number of trackable V(D)J sequences decreased from 3 at baseline to 2 during subsequent MRD testing. Among the BM MRDpos samples, 32% had 1-10 tumor cells per million, corresponding to a sensitivity range of 10-5 to 10-6. Additionally, 40% of samples achieved a sensitivity greater than 10-5 and 28% achieved a sensitivity greater than 10-6. Notably, in 28%, residual disease was detectable only at a sensitivity of 10-6, which would have been classified as MRDneg by less sensitive assays. Of the 725 (51%) BM MRDneg samples, the median number of cells analyzed was 2.8 million (range: 0.04–6.29 million). Of these, 604 (83%) of samples assessed at least 1 million cells, achieving a sensitivity of 10-6.

Conclusions: Identification of a baseline trackable ID was successful in the majority of MM patients. With a substantial proportion of MRD tests achieving a sensitivity of 10-6 and over a quarter of positive samples having residual disease detectable only at a 10-6 sensitivity, these findings support the feasibility of achieving deep MRD sensitivities in real-world clinical practice and support future research in the optimal sensitivity thresholds for MRD assessment beyond 10-5 that may further improve patient outcomes.

Jessica M. Kent, N/A: No relevant conflicts of interest to declare.